BELLICUM PHARMACEUTICALS, INC 4
4 · BELLICUM PHARMACEUTICALS, INC · Filed Aug 17, 2016
Insider Transaction Report
Form 4
Slawin Kevin M.
DirectorCMO and CTO
Transactions
- Sale
Common Stock
2016-08-15$20.01/sh−1,873$37,470→ 98,206 total - Sale
Common Stock
2016-08-15$19.27/sh−34,127$657,542→ 100,079 total - Sale
Common Stock
2016-08-15$19.27/sh−29,000$558,911→ 370,982 total(indirect: By Trust) - Sale
Common Stock
2016-08-15$20.01/sh−2,000$40,020→ 368,982 total(indirect: By Trust)
Holdings
- 398,067(indirect: By Trust)
Common Stock
Footnotes (7)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 23, 2016 by the Reporting Person.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.99 to $19.98. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.95 to $19.9288. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F5]The Reporting Person's spouse is trustee of the Jordana Slawin 2012 Family Trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- [F6]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.97 to $20.05. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F7]The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.